Renal cell carcinoma:An update for the practicing urologist  

作　　者：Sumanta K.Pal Paulo Bergerot Robert A.Figlin 

机构地区：[1]Department of Medical Oncology&Experimental Therapeutics,City of Hope Comprehensive Cancer Center,Duarte,CA,USA [2]Health Department of Federal District(SES)e HRAN,Brasilia,Brazil [3]Department of Medicine,Cedars-Sinai Medical Center,Los Angeles,CA,USA

出　　处：《Asian Journal of Urology》2015年第1期19-25,共7页亚洲泌尿外科杂志（英文）

摘　　要：Systemic therapy for metastatic renal cell carcinoma(mRCC)has evolved drastically,with agents targeting vascular endothelial growth factor(VEGF)and the mammalian target of rapamycin(mTOR)now representing a standard of care.The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing.(1)Though observation remains a standard of care following resection of localized disease,multiple trials are underway to assess VEGF-and mTOR-directed therapies in this setting.(2)While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents,prospective data to support this approach is still forthcoming.(3)The first-line management of mRCC may change substantially with multiple studies exploring vaccines,immune checkpoint inhibitors,and novel targeted agents currently underway.In general,prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy.Over the same span of time,the current treatment paradigm for first-line therapy may evolve.

关 键 词：Renal cell carcinoma Sdjuvant therapy Cytoreductive nephrectomy Vaccines IMMUNOTHERAPY PD-1 Cabozantinib 

分 类 号：R73[医药卫生—肿瘤]